Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant

Flores, J.; Balderas, M. Lozano; Bonilla, M. Cortés; Vázquez-Estrada, L.

doi:10.1016/j.ijgo.2005.06.007

Cited by 41 publications

(40 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No pregnancies occurred in other post-marketing surveillance 12,13 or clinical studies, 14 confirming the need for health care providers to undergo proper training and certification before providing the service.…”

mentioning

confidence: 85%

Failure of Implanon® on antituberculous therapy

Gbolade¹

2010

OAJC

View full text Add to dashboard Cite

Implanon ® , a contraceptive implant, is increasingly being used because of its efficacy and nonuser-dependent nature. However, as for other steroid contraceptives, its efficacy can be reduced by enzyme-inducing drugs, such as antituberculous medication, resulting in unplanned pregnancy. We present the case of a 27-year-old para 1 + 0 referred to us for termination of a pregnancy that resulted from failure of Implanon during concomitant treatment with Rifinah ® (a rifampicin-isoniazid combination). All health care providers should be aware of the adverse effects of hepatic enzyme inducers on hormonal contraceptives, obtain details of current contraceptive methods from women of reproductive age, and refer them to contraceptive and reproductive health care professionals as appropriate for optimal management. This will ensure that such women do not experience the psychologic trauma of a termination of pregnancy.

show abstract

mentioning

confidence: 85%

Failure of Implanon® on antituberculous therapy

Gbolade¹

2010

OAJC

View full text Add to dashboard Cite

show abstract

“…25 Overall, this study enrolled women with a mean weight of 59.4 ± 9.3 kg and a mean BMI of 24.9 ± 3.9, with 19.4% of subjects categorized as overweight (BMI>25) and 8.9% categorized as obese (BMI>30). Once again, no pregnancies were recorded in this study, which corresponded to 958.5 women-years of observation.…”

Section: Efficacymentioning

confidence: 99%

The Contraceptive Implant

Hohmann

Creinin²

2007

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Contraceptive implants provide long-acting, highly effective reversible contraception. Currently, the only subdermal implant available to women in the United States is the single rod etonogestrel implant, Implanon (N.V. Organon, Oss, the Netherlands) approved by the Food and Drug Administration in July 2006. Implanon is currently approved for 3 years of use, provides excellent efficacy throughout its use, and is easy to insert and remove. Similar to other progestin-only contraceptives, Implanon can cause irregular vaginal bleeding. Implanon has been shown to be safe to use during lactation, may improve dysmenorrhea, and does not significantly affect bone mineral density, lipid profile, or liver enzymes.

show abstract

“…The literature demonstrates that Jadelle and Norplant are similar in many respects, except in the higher incidence of removal-related adverse events that occurred more with Norplant 101112. The main contraceptive mechanism of these implants is the inhibition of ovulation through the suppression of the luteinizing hormone surge.…”

Section: Introductionmentioning

confidence: 99%

Sociodemographic profiles and use-dynamics of Jadelle (levonorgestrel) implants in Jos, Nigeria

et al. 2016

View full text Add to dashboard Cite

Background:Contraceptive implants (including Jadelle) are highly effective, safe, and easy to use and have a long duration of action. They do not interfere with intercourse with immediate return to fertility after removal. However, disruption of the menstrual bleeding pattern is almost inevitable and coercive prescription may be a problem because insertion and removal of implants are provider dependent. The objective of this study was to determine the sociodemographic profiles of acceptors of Jadelle and the reasons for discontinuation in Jos, Nigeria.Materials and Methods:This was a 6-year retrospective chart review carried out at the Jos University Teaching Hospital.Results:About 1401 women accepted Jadelle with a mean (±standard deviation) of 33.4 ± 5.9 years. About 88% of the women were Christians and almost three-quarters (73.5%) had at least secondary school education. The means of parity and number of children still alive at the time of accepting Jadelle were 4.1 and 3.8, respectively. Half of the women (49.5%) were breastfeeding and over half (55.9%) had future fertility desires at the time of commencing Jadelle. About 82% had previously used other contraceptives (mostly short-acting methods such as injectables, pills, and condoms), with only 18% starting Jadelle as the first-ever contraceptive method. About 90% of the women had regular menstrual cycles. The major reason for discontinuation of Jadelle was desire for pregnancy although menstrual pattern disruption was the most common reason for removal in the first 6 months of use.Conclusion:The main reason for discontinuation of Jadelle was to have more children although menstrual pattern disruptions accounted for earlier discontinuation.

show abstract

Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant

Abstract: Etonogestrel subdermal contraceptive implants demonstrated high efficacy and an acceptable continuation rate. Counseling potential users explicitly about the side effects will optimize patient success with this long-acting contraceptive.

Cited by 41 publications

References 18 publications

Failure of Implanon® on antituberculous therapy

Failure of Implanon® on antituberculous therapy

The Contraceptive Implant

Sociodemographic profiles and use-dynamics of Jadelle (levonorgestrel) implants in Jos, Nigeria

Contact Info

Product

Resources

About

Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant

Abstract: Etonogestrel subdermal contraceptive implants demonstrated high efficacy and an acceptable continuation rate. Counseling potential users explicitly about the side effects will optimize patient success with this long-acting contraceptive.

Cited by 41 publications

References 18 publications

Failure of Implanon&reg; on antituberculous therapy

Failure of Implanon&reg; on antituberculous therapy

The Contraceptive Implant

Sociodemographic profiles and use-dynamics of Jadelle (levonorgestrel) implants in Jos, Nigeria

Contact Info

Product

Resources

About

Failure of Implanon® on antituberculous therapy

Failure of Implanon® on antituberculous therapy